Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 21.52 4.21% 0.87
SPPI closed up 4.21 percent on Thursday, September 20, 2018, on 1.25 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical SPPI trend table...

Date Alert Name Type % Chg
Sep 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Sep 20 Wide Bands Range Expansion 0.00%
Sep 20 Up 3 Days in a Row Strength 0.00%
Sep 20 Up 4 Days in a Row Strength 0.00%
Sep 20 Up 5 Days in a Row Strength 0.00%
Sep 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.21%
Sep 19 Wide Bands Range Expansion 4.21%
Sep 19 Up 3 Days in a Row Strength 4.21%
Sep 19 Up 4 Days in a Row Strength 4.21%
Sep 19 Oversold Stochastic Weakness 4.21%

Older signals for SPPI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 25.29
52 Week Low 9.55
Average Volume 1,270,031
200-Day Moving Average 19.9342
50-Day Moving Average 22.0854
20-Day Moving Average 21.7805
10-Day Moving Average 20.484
Average True Range 1.0261
ADX 15.8
+DI 25.6778
-DI 22.1791
Chandelier Exit (Long, 3 ATRs ) 22.2117
Chandelier Exit (Short, 3 ATRs ) 22.4083
Upper Bollinger Band 25.1484
Lower Bollinger Band 18.4126
Percent B (%b) 0.46
BandWidth 30.925828
MACD Line -0.5178
MACD Signal Line -0.449
MACD Histogram -0.0688
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -21.52
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.02
Resistance 3 (R3) 22.87 22.21 22.77
Resistance 2 (R2) 22.21 21.83 22.29 22.69
Resistance 1 (R1) 21.87 21.60 22.04 22.02 22.60
Pivot Point 21.21 21.21 21.30 21.29 21.21
Support 1 (S1) 20.87 20.83 21.04 21.02 20.44
Support 2 (S2) 20.21 20.60 20.29 20.35
Support 3 (S3) 19.87 20.21 20.27
Support 4 (S4) 20.02